VG Life Sciences Reports Positive Safety Results From Second Cohort Enrollment In Solid Tumor Clinical Trial
SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar ®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
Haig Keledjian, CEO of VG Life Sciences, said, "We are happy to report we attained the safety endpoints we anticipated for our second cohort of patients. Similar to the positive results we announced previously for our first patient cohort, no significant toxicities were observed at a higher dose of HCQ in combination with sorafenib. We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion. We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013."
Dr. Tyler Curiel, gynecological oncologist at the Cancer Therapy & Research Center in San Antonio, TX, and principal investigator for the trial said, "Having successfully finished enrollment in cohort two, we have begun treating patients in the third cohort. The safety of our patients is paramount and these results give us the needed information so that we can continue advancing in this next cohort. The purpose of this study is to establish the safety profile and determine appropriate doses of this combination of anti-cancer drugs."
The trial is supported by a donation from the Scott and White Foundation.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV